Moderna (WBO:MRNA) Beginning Cash Position : €2,694 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Moderna Beginning Cash Position?

Moderna's Beginning Cash Position for the quarter that ended in Mar. 2024 was €2,694 Mil.

Moderna's quarterly Beginning Cash Position declined from Sep. 2023 (€3,581 Mil) to Dec. 2023 (€2,708 Mil) and declined from Dec. 2023 (€2,708 Mil) to Mar. 2024 (€2,694 Mil).

Moderna's annual Beginning Cash Position increased from Dec. 2021 (€2,333 Mil) to Dec. 2022 (€6,476 Mil) but then declined from Dec. 2022 (€6,476 Mil) to Dec. 2023 (€2,950 Mil).

Moderna Beginning Cash Position Historical Data

The historical data trend for Moderna's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Beginning Cash Position Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

603.00

203.86

2,332.86

6,475.84

2,949.99

Moderna Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															3,004.68	3,194.50	3,581.21	2,707.90	2,693.76

Moderna Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Moderna Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Moderna's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Moderna (WBO:MRNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (WBO:MRNA) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Peru MRNA:Mexico 0QFd:UK 0A45:UK 0QF:Germany M1RN34:Brazil

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.